Collin Hovinga, PharmD, MS, FCCP
SVP, Clinical and Scientific Development
Dr. Hovinga earned his Bachelor of Science and Doctor of Pharmacy degrees from Creighton University in Omaha, Nebraska. He completed a Residency and Fellowship in Pediatric Pharmacotherapy with emphasis in Pediatric Neuroscience at the University of Tennessee, Memphis, LeBonheur Children’s Medical Center. He completed a second a Fellowship at the Food and Drug Administration Office of Clinical Pharmacology and a Masters of Epidemiology from the University of Tennessee Health Science Center. He has additional training in outcomes research from MD Anderson Cancer Center. Dr. Hovinga is recognized as an expert in pediatric pharmacology and has held appointments with the FDA’s Peripheral and Central Nervous System Advisory Committee. Dr. Hovinga has had key roles in pediatric interventional clinical trials and neuroprotective drug pharmacology NIH projects. He was most recently Chair of ACCP’s Practice Based Research Advisory Committee. He has been active as a leader in practice-based guidelines and evidence-based medicine projects for the American Academy of Neurology and American Epilepsy Society. He is a recognized consultant in the conduct of pediatric clinical trials, with expertise in ethical and methodological issues, as well as patient reported outcomes. Dr. Hovinga’s understanding of developmental pharmacology and pediatric medical conditions has made him unique in the pharmacology arena and has led to him being a journal reviewer and an invited speaker at many national organizational meetings. He is active as a board member and advocate in many pediatric rare medical conditions and is currently a Clinical Associate Professor at the University of Texas at Austin.